

Supplementary Table S1. Liver function in pregnant women during pregnancy

Values	All patients (n = 420)	Group A (n = 142)	Group B (n=121)	Group C (n=157)	H/ χ^2	P	P group A vs. B	P group A vs. C	P group B vs. C
Early ALT	15 (11, 25)	13 (10, 18)	13 (9, 20)	21 (16, 36)	80.167	<0.001	>0.999	<0.001	<0.001
Early AST	17 (14, 22)	15 (13, 19)	15 (13, 18)	21 (17, 28)	76.572	<0.001	>0.999	<0.001	<0.001
Early TBIL	8.90 (7.50, 10.80)	8.70 (7.30, 10.20)	8.70 (7.05, 10.30)	9.30 (7.85, 11.65)	9.668	0.008	>0.999	0.038	0.016
	43.50 (40.63, 46.00)	44.60 (42.95, 46.73)	44.20 (41.90, 46.50)	41.70 (39.00, 44.10)					
Early ALB	46.00	46.73	46.50	44.10	54.874	<0.001	0.22	<0.001	<0.001
Middle ALT	13 (10, 20)	11 (8, 17)	11 (8, 15)	17 (12, 26)	69.477	<0.001	>0.999	<0.001	<0.001
Middle AST	35 (34, 37)	15 (12, 17)	15 (12, 18)	19 (15, 24)	61.953	<0.001	>0.999	<0.001	<0.001
Middle TBIL	7.20 (5.90, 8.70)	7.10 (5.70, 8.30)	6.80 (5.70, 8.30)	7.50 (6.30, 9.90)	10.808	0.004	>0.999	0.031	0.008
	37.70 (36.20, 39.30)	38.20 (36.80, 39.60)	38.30 (37.05, 39.80)	36.80 (35.60, 38.35)					
Middle ALB	39.30	39.60	39.80	38.35	28.414	<0.001	>0.999	<0.001	<0.001
Late ALT	11 (8, 16)	9 (7, 12)	9 (7, 12)	16 (11, 24)	94.277	<0.001	>0.999	<0.001	<0.001
Late AST	16 (14, 20)	15 (13, 18)	15 (13, 18)	19 (15, 24)	66.029	<0.001	>0.999	<0.001	<0.001
				8.20 (6.40, 10.35)					
Late TBIL	7.55 (6.20, 9.80)	7.30 (5.80, 9.00)	7.00 (6.15, 9.35)	10.35)	9.832	0.007	>0.999	0.018	0.029
	36.00 (34.50, 37.60)	36.55 (35.00, 37.53)	36.60 (35.05, 38.75)	35.20 (33.40, 36.70)					
Late ALB	37.60	37.53	38.75	36.70	28.729	<0.001	0.856	<0.001	<0.001
Abnormal									
early ALT	160 (38.10%)	34 (23.94%)	32 (26.45%)	94 (59.87%)	50.594	<0.001	>0.999	<0.001	<0.001
Abnormal									
early AST	29 (6.90%)	0	4 (3.31%)	25 (15.92%)	32.837	<0.001	>0.999	<0.001	0.002
Abnormal									
early TBIL	10 (2.38%)	3 (2.11%)	1 (0.83%)	6 (3.82%)	2.437	0.284	>0.999	>0.999	0.697
Abnormal									
early ALB	81 (19.29%)	8 (5.63%)	23 (19.01%)	50 (31.85%)	32.922	<0.001	<0.001	<0.001	0.048
Abnormal									
middle ALT	115 (27.38%)	27(19.01%)	19 (15.70%)	69 (43.95%)	34.973	<0.001	>0.999	<0.001	<0.001
Abnormal									
middle AST	15 (3.57%)	0	2 (1.65%)	13 (8.28%)	16.08	<0.001	0.633	0.001	0.046
Abnormal									
middle TBIL	4 (0.95%)	1 (0.70%)	1 (0.83%)	2 (1.27%)	0.492	>0.999	>0.999	>0.999	>0.999
Abnormal									
middle ALB	347 (82.61%)	115 (80.99%)	93 (76.86%)	13 (88.54%)	6.885	0.032	>0.999	>0.999	0.028
Abnormal									
late ALT	88 (20.95%)	9 (6.34%)	13 (10.74%)	66 (42.04%)	68.071	<0.001	0.594	<0.001	<0.001
Abnormal									
late AST	14 (3.33%)	1 (0.70%)	2 (1.65%)	11 (7.01%)	9.526	0.006	>0.999	0.018	0.108
Abnormal	7 (1.67%)	2 (1.41%)	1 (0.83%)	4 (2.55%)	1.160	0.635	>0.999	>0.999	>0.999

late TBIL									
Abnormal									
late ALB	393 (93.58%)	136 (95.77%)	108 (89.26%)	149 (94.90%)	5.355	0.069	>0.999	>0.999	0.232

Note. Ps: Group A: anti-HCV(-) and HCV RNA (-); Group B: anti-HCV (+) and HCV RNA (-); Group C: anti-HCV (+) and HCV RNA (+). $P < 0.05$ indicates a statistically significant difference.

Table S2. Binary logistic regression analysis of neonatal jaundice

Values	Univariate analysis				multivariate analysis			
	<i>B</i>	<i>OR</i>	95% <i>CI</i>	<i>P</i> -value	<i>B</i>	<i>OR</i>	95% <i>CI</i>	<i>P</i> -value
HCV RNA (+)	0.82	2.28	1.369-3.799	0.002	0.747	2.111	1.242-3.588	0.006
Han Chinese								
(<i>n</i> , %)	21.95	3394314093.69	/	0.999				
Ages (year)	-0.02	0.98	0.930-1.041	0.564				
Gestation								
(weeks)	-0.02	0.98	0.916-1.052	0.598				
Gravidity								
(times)	-0.09	0.92	0.723-1.164	0.479				
Parity (times)	-0.32	0.73	0.443-1.198	0.212				
Cesarean								
(<i>n</i> , %)	-0.41	0.66	0.398-1.100	0.111				
History of adverse pregnancy								
(<i>n</i> , %)	-0.20	0.82	0.490-1.358	0.434				
Male (<i>n</i> , %)	-0.05	0.95	0.575-1.570	0.843				
Weight (g)	0.00	1.00	0.999-1.000	0.698				
length (cm)	0.17	1.19	0.890-1.594	0.241				
APgar score at 5 min (scores)	1.42	4.14	0.786-21.852	0.094				
APgar score at 10 min (scores)	1.43	4.18	0.374-46.711	0.245				
ePisiotomy								
(<i>n</i> , %)	0.50	1.65	0.866-3.154	0.127				
Birth defect (<i>n</i> , %)	-0.33	0.72	0.198-2.621	0.619				
Intrauterine								
distress (<i>n</i> , %)	-0.94	0.39	0.116-1.311	0.128				
nuchal cords (<i>n</i> , %)	-0.78	0.46	0.263-0.791	0.005	-0.741	0.476	0.269-0.844	0.011
Oligohydramnios								
(<i>n</i> , %)	-0.39	0.68	0.249-1.843	0.446				
Premature ruPture of membranes (<i>n</i> , %)	1.04	2.82	1.130-7.016	0.026	0.889	2.433	0.948-6.245	0.064
PostPartum Hemorrhage (<i>n</i> , %)	0.32	1.38	0.591-3.240	0.455				

Gestational									
Diabetes									
(n, %)	-0.14	0.87	0.527-1.436	0.585					
HyPoThyroidism									
(n, %)	-0.40	0.67	0.206-2.168	0.503					
HyPerTension disorder of Pregnancy									
(n, %)	-0.14	0.87	0.283-2.674	0.807					
Pregnancy with scarred uterus									
(n, %)	-0.60	0.55	0.275-1.104	0.093					
Anemia in Pregnancy									
(n, %)	0.83	2.29	0.839-6.268	0.106					
Erythema neonatorum									
(n, %)	-0.33	0.72	0.198-2.621	0.619					
Premature birth									
(n, %)	-0.56	0.57	0.169-1.920	0.364					
Neonatal hyPoglycemia									
(n, %)	-0.76	0.47	0.275-0.797	0.005	-0.750	0.473	0.272-0.821	0.008	
Abnormal early ALT (n, %)									
ALT (n, %)	0.02	1.02	0.614-1.681	0.950					
Abnormal early AST (n, %)									
AST (n, %)	0.93	2.53	0.933-6.872	0.068					
Abnormal early TBIL (n, %)									
TBIL (n, %)	0.20	1.22	0.233-6.425	0.812					
Abnormal early ALB (n, %)									
ALB (n, %)	0.08	1.08	0.608-1.914	0.795					
Abnormal middle ALT (n, %)									
ALT (n, %)	0.54	1.71	0.971-3.013	0.063					
Abnormal middle AST (n, %)									
AST (n, %)	0.31	1.36	0.421-4.392	0.608					
Abnormal middle TBIL (n, %)									
TBIL (n, %)	20.50	798957666.84	/	0.999					
Abnormal middle ALB (n, %)									
ALB (n, %)	-0.01	0.99	0.506-1.950	0.984					
Abnormal late ALT (n, %)									
ALT (n, %)	0.15	1.16	0.663-2.041	0.598					
Abnormal late AST (n, %)									
AST (n, %)	-0.60	0.55	0.180-1.689	0.297					
Abnormal late TBIL (n, %)									
TBIL (n, %)	-0.32	0.73	0.119-4.420	0.728					
Abnormal late ALB (n, %)									
ALB (n, %)	0.47	1.60	0.649-3.949	0.307					

Note. Ps: Group A: anti-HCV(-) and HCVRNA(-); Group B: anti-HCV(+) and HCVRNA(-); Group C: anti-HCV

(+) and HCV RNA (+). $P < 0.05$ indicates a statistically significant difference.